# **Veraflox Oral Suspension**

Version 5.1 Revision Date 07/27/2017



### 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

Product information VERAFLOX ORAL SUSP 2.5 % 15ML

**Product Name:** Veraflox Oral Suspension

**Synonyms:** PRADO SUSP 2,5 % M/V 5 ML 224 ORAL

Veraflox

**SDS Number:** 122000001946

Use : veterinary medicine

### Company

Bayer HealthCare, LLC Animal Health Division 12707 Shawnee Mission Parkway (West 63rd) Shawnee, KS 66216-1846 UNITED STATES OF AMERICA (800) 633-3796

In case of emergency: (800) 422-9874

Chemtrec: (800) 424-9300

BAYER INFORMATION PHONE: (800) 633-3796

INTERNATIONAL:(703) 527-3887

#### 2. HAZARDS IDENTIFICATION

### Classification of the substance or mixture

### Classification according to national GHS implementation:

Germ cell mutagenicity, Category 2 (H341)

#### Label elements

### Labelling according to national GHS implementation:



#### Warning

# **Hazard statements:**

H341 Suspected of causing genetic defects.

#### **Precautionary statements:**

#### Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

#### Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

# **Veraflox Oral Suspension**

Version 5.1 Revision Date 07/27/2017



Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Hazardous components which must be listed on the label:

**Components:** CAS-No.
Pradofloxacin Drug 195532-12-8

Other hazards

Other hazards which do not result in classification:

None known.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

This product is a mixture.

Aqueous solution

### **Hazardous components**

#### Amberlite IRP 64

Concentration [Weight percent] 9.48

CAS-No.: 80892-32-6 CAS name: Amberlite IRP 64

### **GHS Classification:**

**(!)** 

Eye Irrit. 2A H319

### **Pradofloxacin Drug**

Concentration [Weight percent] 2.37

CAS-No.: 195532-12-8

CAS name: 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-

### **GHS Classification:**



Acute Tox. 4 H302 Muta. 2 H341

#### contains

### Propane-1,2-diol

Concentration [Weight percent] 28.5819

CAS-No.: 57-55-6

CAS name: 1,2-Propanediol (8CI, 9CI)

# **Veraflox Oral Suspension**

Version 5.1 Revision Date 07/27/2017



For the full text of the H-Statements mentioned in this Section, see Section 16.

#### 4. FIRST AID MEASURES

**Description of first aid measures** 

**General advice:** Follow label or package insert instructions.

If inhaled: Remove to fresh air. Call a physician immediately.

**In case of skin contact:** After contact with skin, wash immediately with plenty of soap and water. If skin reactions occur, contact a physician.

**In case of eye contact:** In the case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

If swallowed: If swallowed, seek medical advice immediately and show this container or label.

Most important acute symptoms/effects

Indication of any immediate medical attention and special treatment needed

### 5. FIREFIGHTING MEASURES

### **Extinguishing media**

**Suitable extinguishing media:** Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Unsuitable extinguishing media: High volume water jet

Special hazards arising from the substance or mixture

**Specific hazards during firefighting:** Fire may cause evolution of: Carbon monoxide (CO) Carbon dioxide (CO2)

**Further information:** Prevent fire extinguishing water from contaminating surface water or the ground water system.

Advice for firefighters

**Special protective equipment for firefighters:** In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Follow label or package insert instructions.

**Environmental precautions** 

Methods and materials for containment and cleaning up

**Methods for cleaning up:** Cover spilled product with liquid-binding material (sand, silica gel, acid binder, universal binder, hybilat). Take up mechanically and fill into labeled, closable containers.

# **Veraflox Oral Suspension**

122000001946 Version 5.1 Revision Date 07/27/2017 Print Date 02/26/2019

Reference to other sections

Additional advice: No special precautions required.

#### 7. HANDLING AND STORAGE

### Precautions for safe handling

### Handling:

Avoid formation of aerosol. Only handle product with local exhaust ventilation. Avoid contact with skin, eyes and clothing.

No special protective measures against fire required.

Conditions for safe storage, including any incompatibilities

Specific end use(s)

# 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Propane-1,2-diol	57-55-6	TWA	10 mg/m3	US WEEL
Pradofloxacin Drug	195532-12-8	OEL (Bayer)	0.5 mg/m <sup>3</sup>	

### Hazardous components without workplace control parameters

Components	CAS-No.
Amberlite IRP 64	80892-32-6

### Personal protective equipment

Respiratory protection Recommended Filter type:

Organic vapor with prefilter

None required for consumer use of this product.

Hand protection

Material Chemically resistant gloves.

Remarks : None required for consumer use of this product.

Eye protection Safety glasses

None required for consumer use of this product.

Protective measures Wear suitable protective equipment.

Please consult label for end-user requirements.

# **Veraflox Oral Suspension**

Version 5.1 Revision Date 07/27/2017



### 9. PHYSICAL AND CHEMICAL PROPERTIES

# Information on basic physical and chemical properties

Form: suspension

Colour: No statements available.
Odour: No statements available.
Melting point/range: No statements available.
Boiling point/boiling range: No statements available.
Density: 1.055 g/cm³ at 20 °C

Bulk density: Not applicable

Vapour pressure:

Viscosity, dynamic:

Viscosity, kinematic:

Flow time:

Surface tension:

Water solubility:

Solubility(ies):

No statements available.

pH: 5 DIN 51369

Corrosive to metal:

Partition coefficient
(n-octanol/water):

No statements available.

Pradofloxacin Drug
log Pow: 0.42

Flash point: No statements available.

Inflammability (solid, gaseous): Not applicable

Explosion limits: No statements available.

Other information

Miscibility with water: No statements available.

### 10. STABILITY AND REACTIVITY

#### Reactivity

No statements available.

### Reactions with water / air:

No statements available.

# Ignition temperature:

**Pradofloxacin Drug** 

> 500 °C

**Burning number:** 

### **Pradofloxacin Drug**

1 at 20 °C Method: VDI 2263

### **Chemical stability**

No statements available.

# **Veraflox Oral Suspension**

Version 5.1 Revision Date 07/27/2017



Thermal decomposition:

No data available

**Dust explosion characteristic number:** 

Not applicable

**Dust explosion class:** 

Not applicable

Impact sensitivity:

No data available

Hazardous reactions:

No data available

**Explosive properties:** 

No statements available.

Possibility of hazardous reactions

deflagration ability:

No statements available.

Smoldering combustion:

No statements available.

Conditions to avoid

No data available

Minimum ignition energy:

No data available

Oxidizing properties:

No statements available.

Incompatible materials

Materials to avoid:

Oxidizing agents

**Hazardous decomposition products** 

Carbon monoxide (CO), Carbon dioxide (CO2)

# 11. TOXICOLOGICAL INFORMATION

**Acute toxicity** 

Product:

Acute oral toxicity : LD50 (Rat): >= 5,000 mg/kg

Method: OECD 423

Assessment: No adverse effect has been observed in acute

toxicity tests.

Acute dermal toxicity : LD50 (Rat): > 4,000 mg/kg

Assessment: May be harmful in contact with skin.

# **Veraflox Oral Suspension**

Version 5.1 Revision Date 07/27/2017



**Components:** 

Amberlite IRP 64:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

: LD50 (Rabbit): > 5,000 mg/kg Acute dermal toxicity

Pradofloxacin Drug:

Acute oral toxicity : LD50 (Rat): 1,000 - 2,000 mg/kg

Assessment: Harmful if swallowed.

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Assessment: May be harmful in contact with skin.

Acute toxicity (other routes of : LD50 (Rat): 200 - 500 mg/kg

administration)

Application Route: intraperitoneal

#### Skin corrosion/irritation

# **Product:**

Species: Rabbit Method: OECD 404 Result: No skin irritation

# **Components:**

# **Pradofloxacin Drug:**

Species: Rabbit Method: OECD 404 Result: No skin irritation

### Serious eye damage/eye irritation

### **Product:**

Species: Rabbit

Result: No eye irritation Method: OECD 405

### **Components:**

### Amberlite IRP 64:

Species: Rabbit

Result: Moderate eye irritation

### **Pradofloxacin Drug:**

Species: Rabbit

Result: No eye irritation Method: OECD 405

# **Veraflox Oral Suspension**

Version 5.1 Revision Date 07/27/2017



# Respiratory or skin sensitisation

**Product:** 

Test Type: Skin sensitisation

Species: Pig Method: OECD 406

Result: Did not cause sensitisation on laboratory animals.

**Components:** 

**Pradofloxacin Drug:** 

Test Type: Skin sensitisation

Species: Guinea pig

Method: Magnusson and Kligmann maximization test

Result: Does not cause skin sensitisation.

Germ cell mutagenicity

**Components:** 

Amberlite IRP 64:

Genotoxicity in vitro : Test Type: Ames test

Result: negative

**Pradofloxacin Drug:** 

Genotoxicity in vitro : Test Type: Micronucleus test

Result: positive

Test Type: Chromosome aberration test in vitro

Result: positive

: Test Type: V79-HPRT Forward Mutation Assay

Result: positive

: Test Type: Ames test

Result: positive

Genotoxicity in vivo : Method: Dominant lethale test

Result: negative

Test Type: Micronucleus test

Species: Mouse Result: positive

Test Type: DNA damage and/or repair

Species: Rat Result: negative

Remarks: The genotoxic effect is attributable to the

pharmacological mechanism of action.

Germ cell mutagenicity - : Positive result(s) from in vivo somatic cell mutagenicity tests

# Veraflox Oral Suspension

122000001946 Version 5.1 Revision Date 07/27/2017 Print Date 02/26/2019

supported by positive results from in vitro mutagenicity assays Assessment

or chemical structure activity relationship to known germ cell

mutagens

Carcinogenicity

**IARC** No component of this product present at levels greater than or

equal to 0.1% is identified as probable, possible or confirmed

human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or

equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No component of this product present at levels greater than or

equal to 0.1% is identified as a known or anticipated carcinogen

by NTP.

Repeated dose toxicity

Components:

Amberlite IRP 64:

NOAEL: 1,000 mg/kg Exposure time: 90-day

### 12. ECOLOGICAL INFORMATION

**Ecotoxicity** 

Components:

Amberlite IRP 64:

**Ecotoxicology Assessment** 

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Pradofloxacin Drug:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): 1,000 mg/l

Exposure time: 96 h

Test Type: Acute Fish toxicity Test substance: Ciprofloxacin HCI

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 176 mg/l

Exposure time: 24 h

Test substance: Ciprofloxacin HCI

Toxicity to algae : EC50 (Desmodesmus subspicatus (green algae)): 33 mg/l

Exposure time: 72 h

Test Type: Cell multiplication inhibition test

Test substance: Ciprofloxacin HCI

# **Veraflox Oral Suspension**

Version 5.1 Revision Date 07/27/2017



Persistence and degradability

No data available

**Bioaccumulative potential** 

**Components:** 

Pradofloxacin Drug:

Partition coefficient: n-

octanol/water

: log Pow: 0.42

Mobility in soil

No data available

Other adverse effects

Product:

Additional ecological

information

: Do not allow to enter surface waters or groundwater.

### 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : If discarded in its purchased form, this product would not be a

hazardous waste either by listing or by characteristic.

However, under RCRA, it is the responsibility of the product user to determine at the time of disposal, whether a material containing the product or derived from the product should be classified as a hazardous waste. (40 CFR 261.20-24)

### 14. TRANSPORT INFORMATION

US Land transport (CFR)

non-regulated

Sea transport (IMDG)

non-regulated

Air transport (IATA)

non-regulated

# **Veraflox Oral Suspension**

Version 5.1 Revision Date 07/27/2017



#### 15. REGULATORY INFORMATION

### **EPCRA - Emergency Planning and Community Right-to-Know Act**

### **CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

# SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 311/312 Hazards : Chronic Health Hazard

SARA 302 : This material does not contain any components with a section

302 EHS TPQ.

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

**US State Regulations** 

Massachusetts Right To Know

No components are subject to the Massachusetts Right to

Know Act.

Pennsylvania Right To Know

Propane-1,2-diol 57-55-6

**New York City Hazardous Substances** 

No components listed on the New York City Hazardous

Substances List

California Prop. 65 This product does not contain any chemicals known to State

of California to cause cancer, birth defects, or any other

reproductive harm.

The components of this product are reported in the following inventories:

Breakdown of the preparation yields at least one new

substance.

TSCA Not On TSCA Inventory

Amberlite IRP 64 Pradofloxacin Drug

**TSCA list** 

No substances are subject to TSCA 12(b) export notification requirements.

No substances are subject to a Significant New Use Rule.

#### 16. OTHER INFORMATION

Full text of H-Statements mentioned in chapters 2 and 3

H302 Harmful if swallowed.

# **Veraflox Oral Suspension** Version 5.1



H319 Causes serious eye irritation.

H341 Suspected of causing genetic defects.

### **Further information**

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.